Straits Times Index
3,363.68 -13.97 (-0.41%) S&P 500
4,119.21 +42.61 (+1.05%) Dow
34,092.96 +6.92 (+0.02%) Nasdaq
11,816.32 +231.77 (+2.00%) BTC-USD
23,808.75 +802.10 (+3.49%) CMC Crypto 200
543.17 +300.49 (+123.82%)
Baxter International Inc. (BAX)
Pre-market:
| Previous close | 45.69 |
| Open | 45.89 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 1400 |
| Day's range | 45.29 - 46.37 |
| 52-week range | 43.25 - 89.70 |
| Volume | |
| Avg. volume | 5,329,878 |
| Market cap | 23.331B |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | 23.14 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.16 (2.52%) |
| Ex-dividend date | 01 Dec 2022 |
| 1y target est | N/A |
- Business Wire
Miromatrix and Baxter Announce Collaborative Research Agreement Aiming to Advance Care for Patients with Acute Liver Failure
EDEN PRAIRIE, Minn. & DEERFIELD, Ill., February 01, 2023--Miromatrix Medical Inc. (NASDAQ: MIRO) and Baxter International Inc. (NYSE:BAX) today announced a collaborative research agreement to help support additional treatment options for patients with acute liver failure (ALF) in need of organ support therapies. As part of the collaboration, Miromatrix has created a new liver therapy called miroliverELAP that combines a Miromatrix single-use bioengineered liver with Baxter’s PrisMax system. Miro
- Business Wire
Baxter to Host Fourth-Quarter 2022 Financial Results Conference Call for Investors
DEERFIELD, Ill., January 11, 2023--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2022 financial results on Thursday, February 9, 2023 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/EmxweYhQ to pre-register for the call and receive the call information.
- Business Wire
Baxter Announces Strategic Actions to Enhance Operational Effectiveness, Accelerate Innovation for Patients and Drive Value for Shareholders
DEERFIELD, Ill., January 06, 2023--Baxter International Inc. (NYSE:BAX), a leading global medtech company, today announced a comprehensive strategic roadmap to meaningfully enhance its operational effectiveness, drive toward improved long-term performance, accelerate innovation and create additional value for all stakeholders. These changes include the plan to spin off the company’s Renal Care and Acute Therapies global business units (GBUs) into an independent, publicly traded company; a simpli
